Clinical and Biologic Significance of MYC Genetic Mutations in De Novo Diffuse Large B-cell Lymphoma

Purpose: MYC is a critical driver oncogene in many cancers, and its deregulation in the forms of translocation and overexpression has been implicated in lymphomagenesis and progression of diffuse large B-cell lymphoma (DLBCL). The MYC mutational profile and its roles in DLBCL are unknown. This study aims to determine the spectrum of MYC mutations in a large group of patients with DLBCL, and to evaluate the clinical significance of MYC mutations in patients with DLBCL treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) immunochemotherapy. Experimental Design: We identified MYC mutations in 750 patients with DLBCL using Sanger sequencing and evaluated the prognostic significance in 602 R-CHOP–treated patients. Results: The frequency of MYC mutations was 33.3% at the DNA level (mutations in either the coding sequence or the untranslated regions) and 16.1% at the protein level (nonsynonymous mutations). Most of the nonsynonymous mutations correlated with better survival outcomes; in contrast, T58 and F138 mutations (which were associated with MYC rearrangements), as well as several mutations occurred at the 3′ untranslated region, correlated with significantly worse survival outcomes. However, these mutations occurred infrequently (only in approximately 2% of DLBCL). A germline SNP encoding the Myc-N11S variant (observed in 6.5% of the study cohort) was associated with significantly better patient survival, and resulted in reduced tumorigenecity in mouse xenografts. Conclusions: Various types of MYC gene mutations are present in DLBCL and show different impact on Myc function and clinical outcomes. Unlike MYC gene translocations and overexpression, most MYC gene mutations may not have a role in driving lymphomagenesis. Clin Cancer Res; 22(14); 3593–605. ©2016 AACR.

[1]  W. Choi,et al.  Clinical features, tumor biology, and prognosis associated with MYC rearrangement and Myc overexpression in diffuse large B-cell lymphoma patients treated with rituximab-CHOP , 2015, Modern Pathology.

[2]  W. Choi,et al.  Clinical and biological significance of de novo CD5+ diffuse large B-cell lymphoma in Western countries , 2015, Oncotarget.

[3]  G. Evan,et al.  BIM is the primary mediator of MYC-induced apoptosis in multiple solid tissues. , 2014, Cell reports.

[4]  D. Dill,et al.  MYC through miR-17-92 suppresses specific target genes to maintain survival, autonomous proliferation, and a neoplastic state. , 2014, Cancer cell.

[5]  S. Lowe,et al.  A common functional consequence of tumor-derived mutations within c-MYC , 2014, Oncogene.

[6]  Dereje D. Jima,et al.  The genomic landscape of mantle cell lymphoma is related to the epigenetically determined chromatin state of normal B cells. , 2014, Blood.

[7]  P. Boutros,et al.  MYC phosphorylation at novel regulatory regions suppresses transforming activity. , 2013, Cancer research.

[8]  W. Choi,et al.  MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program. , 2013, Blood.

[9]  A. Rosenwald,et al.  MYC status in concert with BCL2 and BCL6 expression predicts outcome in diffuse large B-cell lymphoma. , 2013, Blood.

[10]  W. Choi,et al.  Patients with diffuse large B-cell lymphoma of germinal center origin with BCL2 translocations have poor outcome, irrespective of MYC status: a report from an International DLBCL rituximab-CHOP Consortium Program Study , 2013, Haematologica.

[11]  Dereje D. Jima,et al.  The genetic landscape of mutations in Burkitt lymphoma , 2012, Nature Genetics.

[12]  L. Staudt,et al.  Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  K. Dybkær,et al.  Comprehensive gene expression profiling and immunohistochemical studies support application of immunophenotypic algorithm for molecular subtype classification in diffuse large B-cell lymphoma: a report from the International DLBCL Rituximab-CHOP Consortium Program Study , 2012, Leukemia.

[14]  L. Staudt,et al.  Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics , 2012, Nature.

[15]  Ryan D. Morin,et al.  BCL2 mutations in diffuse large B-cell lymphoma , 2012, Leukemia.

[16]  R. Spang,et al.  Deep Sequencing of MYC DNA-Binding Sites in Burkitt Lymphoma , 2011, PloS one.

[17]  Raul Rabadan,et al.  Analysis of the Coding Genome of Diffuse Large B-Cell Lymphoma , 2011, Nature Genetics.

[18]  Kefei Yu,et al.  Overlapping activation-induced cytidine deaminase hotspot motifs in Ig class-switch recombination , 2011, Proceedings of the National Academy of Sciences.

[19]  Javier Santos,et al.  Combinatorial effects of microRNAs to suppress the Myc oncogenic pathway. , 2011, Blood.

[20]  M. Troxell,et al.  Phosphorylation regulates c-Myc's oncogenic activity in the mammary gland. , 2011, Cancer research.

[21]  M. Nussenzweig,et al.  Origin of Chromosomal Translocations in Lymphoid Cancer , 2010, Cell.

[22]  Thomas Ried,et al.  AID produces DNA double-strand breaks in non-Ig genes and mature B cell lymphomas with reciprocal chromosome translocations. , 2009, Molecular cell.

[23]  D. Schatz,et al.  Two levels of protection for the B cell genome during somatic hypermutation , 2008, Nature.

[24]  I. Andrulis,et al.  Polymorphisms cMyc-N11S and p27-V109G and breast cancer risk and prognosis , 2007, BMC Cancer.

[25]  L. Staudt,et al.  Aberrant immunoglobulin class switch recombination and switch translocations in activated B cell–like diffuse large B cell lymphoma , 2007, The Journal of experimental medicine.

[26]  S. R. Hann.  Role of post-translational modifications in regulating c-Myc proteolysis, transcriptional activity and biological function. , 2006, Seminars in cancer biology.

[27]  P. Bugert,et al.  c‐MYC Asn11Ser is associated with increased risk for familial breast cancer , 2005, International journal of cancer.

[28]  S. Lowe,et al.  Evasion of the p53 tumour surveillance network by tumour-derived MYC mutants , 2005, Nature.

[29]  S. Lowe,et al.  A conserved element in Myc that negatively regulates its proapoptotic activity , 2005, EMBO reports.

[30]  John L Cleveland,et al.  c-Myc is essential for vasculogenesis and angiogenesis during development and tumor progression. , 2002, Genes & development.

[31]  M. Raffeld,et al.  c-myc box II mutations in Burkitt's lymphoma-derived alleles reduce cell-transformation activity and lower response to broad apoptotic stimuli , 2001, Oncogene.

[32]  C. Dang,et al.  Translocations involving c-myc and c-myc function , 2001, Oncogene.

[33]  Gouri Nanjangud,et al.  Hypermutation of multiple proto-oncogenes in B-cell diffuse large-cell lymphomas , 2001, Nature.

[34]  S. Ralston,et al.  A mutation in the c-myc-IRES leads to enhanced internal ribosome entry in multiple myeloma: A novel mechanism of oncogene de-regulation , 2000, Oncogene.

[35]  M. Cole,et al.  The c-Myc Transactivation Domain Is a Direct Modulator of Apoptotic versus Proliferative Signals , 2000, Molecular and Cellular Biology.

[36]  E. Lander,et al.  Expression analysis with oligonucleotide microarrays reveals that MYC regulates genes involved in growth, cell cycle, signaling, and adhesion. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[37]  L. Larsson,et al.  c-Myc hot spot mutations in lymphomas result in inefficient ubiquitination and decreased proteasome-mediated turnover. , 2000, Blood.

[38]  R. Bernards,et al.  Functional Analysis of Burkitts Lymphoma Mutant c-Myc Proteins (*) , 1996, The Journal of Biological Chemistry.

[39]  M. Raffeld,et al.  Clustered mutations in the second exon of the MYC gene in sporadic Burkitt's lymphoma. , 1993, Oncogene.

[40]  B. Yu,et al.  Somatic mutations in c-myc intron I cluster in discrete domains that define protein binding sequences. , 1993, The Journal of biological chemistry.

[41]  I. Magrath,et al.  Point mutations in the c–Myc transactivation domain are common in Burkitt's lymphoma and mouse plasmacytomas , 1993, Nature Genetics.

[42]  M. Groudine,et al.  Mutations in the first exon are associated with altered transcription of c-myc in Burkitt lymphoma. , 1987, Science.

[43]  P. Leder,et al.  A translocated human c-myc oncogene is altered in a conserved coding sequence. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[44]  P. Pelicci,et al.  Chromosomal breakpoints and structural alterations of the c-myc locus differ in endemic and sporadic forms of Burkitt lymphoma. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[45]  T. Rabbitts,et al.  Effect of somatic mutation within translocated c-myc genes in Burkitt's lymphoma , 1984, Nature.

[46]  P. Leder,et al.  Activation and somatic mutation of the translocated c-myc gene in Burkitt lymphoma cells , 1984, Cell.

[47]  W. Choi,et al.  Rearrangements of MYC gene facilitate risk stratification in diffuse large B-cell lymphoma patients treated with rituximab-CHOP , 2014, Modern Pathology.

[48]  M. Henriksson,et al.  MYC in oncogenesis and as a target for cancer therapies. , 2010, Advances in cancer research.

[49]  J. Woodgett,et al.  Site-specific modulation of c-Myc cotransformation by residues phosphorylated in vivo. , 1994, Oncogene.